“An additional analysis appears to indicate that incidence of COVID-19 generally increased in each [vaccinated] group of study participants with increasing time post-Dose 2..” (FDA Briefing Document from 17 Sept 2021, page 22, section 6.4.6.)
“An additional analysis appears to indicate that incidence of COVID-19 generally increased in each [vaccinated] group of study participants with increasing time post-Dose 2..” (FDA Briefing Document from 17 Sept 2021, page 22, section 6.4.6.)
(post is archived)